Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar;18(3):247-52.

Immunotherapeutic effects of pentoxifylline in type 1 diabetic mice and its role in the response of T-helper lymphocytes

Farin Malekifard  1 , Nowruz Delirezh  1 , Rahim Hobbenaghi  2 , Hassan Malekinejad  3
Affiliations

Immunotherapeutic effects of pentoxifylline in type 1 diabetic mice and its role in the response of T-helper lymphocytes

Farin Malekifard et al. Iran J Basic Med Sci. 2015 Mar.

Abstract

Objectives: Pentoxifylline is an immunomodulatory and anti-inflammatory agent and is used in vascular disorders. It has been shown that pentoxifylline inhibits proinflammatory cytokines production. The purpose of this study was to investigate the therapeutic effects of pentoxifylline on the treatment of autoimmune diabetes in mice.

Materials and methods: Diabetes was induced by multiple low dose of streptozotocin (MLDS) injection (40 mg/kg/day for 5 consecutive days) in male C57BL/6 mice. After induction of diabetes, mice were treated with pentoxifylline (100 mg/kg/day IP) for 21 days. Blood glucose levels and plasma levels of insulin were measured. Splenocytes were tested for proliferation by MTT test and cytokine production by ELISA.

Results: Pentoxifylline treatment prevented hyperglycemia and increased plasma insulin levels in the diabetic mice. Aside from reducing lymphocyte proliferation, pentoxifylline significantly inhibited the production of proinflammatory interleukin 17 (IL-17) as well as interferon gamma (IFN-γ), while increased anti-inflammatory cytokine IL-10 as compared with those in MLDS group (diabetic control group).

Conclusion: These findings indicate that pentoxifylline may have therapeutic effect against the autoimmune destruction of the pancreatic beta-cells during the development of MLDS-induced type 1 diabetes in mice.

Keywords: Cytokine; Pentoxifylline; Type 1 diabetes mellitus.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of pentoxifylline treatment on blood glucose levels (* P<0.05)
Figure 2
Figure 2
Effect of pentoxifylline treatment on plasma levels of insulin (* P<0.05)
Figure 3
Figure 3
Effect of pentoxifylline on productions of IFN γ IL-10 and IL-17 of diabetic murine splenocytes induced by Con A ex vivo (* P<0.05 versus diabetic control group)
Figure 4
Figure 4
Effects of pentoxifylline on the proliferation of splenic lymphocytes induced by con A after 72 hr (*P<0.05)
See this image and copyright information in PMC

References

    1. Atkinson MA, McLaren NK. The pathogenesis of insulin-dependent diabetes mellitus. NEngl J Med. 1994;31:1428–1436. - PubMed
    1. Roep BO, Peakman M. Diabetogenic T lymphocytes in human type 1 diabetes. Curr Opin Immunol. 2011;23:746–753. - PubMed
    1. Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozotocin induced diabetes and non-obese diabetic (NOD) mice. Diabetes Metab Rev. 1987;3:751–778. - PubMed
    1. Hill N, Sarvetnick N. Cytokines: promoters and dampeners of autoimmunity. Curr Opin Immunol. 2002;14:791–797. - PubMed
    1. Miljkovic D, Cvetkovic I, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Interleukin-17 stimulates inducible nitric oxide synthasedependent toxicity in mouse beta cells. Cell Mol Life Sci. 2005;62:2658–2668. - PMC - PubMed

LinkOut - more resources